What is the current market size?

The mRNA Cancer Vaccines and Therapeutics market size was valued at USD 1.2 billion in 2023, driven by advancements in personalized oncology and biotech innovation.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising cancer incidence and mRNA technology adoption.

What are the key growth drivers?

Key drivers include breakthroughs in mRNA platform efficiency, increasing demand for immunotherapies, and growing R&D investments in oncology.

What challenges does the market face?

Challenges include high production costs, complex manufacturing processes, and regulatory uncertainties in approval pathways.

Which regions lead the market?

North America dominates the market due to strong healthcare infrastructure, while Europe and Asia-Pacific show rapid adoption in clinical trials.

Who are the top market players?

Leading companies include Moderna, BioNTech, Merck, and GSK, leveraging mRNA platforms for pipeline expansion and partnerships.

What are the future opportunities?

Opportunities lie in combination therapies, rare cancer targeting, and digital health integration to enhance treatment precision and outcomes.

How is technology shaping the market?

Advances in lipid nanoparticle delivery systems and AI-driven mRNA design are accelerating therapeutic efficacy and reducing development timelines.

What is the regulatory landscape?

Regulators like FDA and EMA prioritize expedited approvals for mRNA oncology candidates, balancing innovation with safety and quality standards.

mRNA Cancer Vaccines and Therapeutics Size, Share & Forecast Analysis 2025–2033

mRNA Cancer Vaccines and Therapeutics by Application (Infectious Disease, Cancer, Others), by Types (Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

mRNA Cancer Vaccines and Therapeutics Market Size | CAGR 22.5 Forecast 2033

mRNA Cancer Vaccines and Therapeutics Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 22.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

mRNA Cancer Vaccines and Therapeutics Market Overview

The mRNA Cancer Vaccines and Therapeutics market encompasses innovative, RNA-based treatments designed to harness the body’s immune system to combat cancer. As a cornerstone of precision oncology, this sector addresses unmet medical needs through personalized, mechanism-driven therapies. The mRNA Cancer Vaccines and Therapeutics market size is projected to experience transformative growth outlook through 2033, driven by advancements in biotechnology and rising demand for targeted cancer immunotherapy. This market forecast underscores industry expansion fueled by breakthroughs in mRNA platform optimization and regulatory tailwinds.

Loading chart…

The global mRNA Cancer Vaccines and Therapeutics market reached $1.2 billion in 2025, with a compound annual growth rate (CAGR) exceeding 28.5% from 2026 to 2033. Key growth drivers include technological innovation in lipid nanoparticle (LNP) delivery systems, which enhances mRNA stability, and regulatory accelerations for personalized oncology solutions. Competitive intensity is rising as biotech giants and startups collaborate to fast-track clinical trials, while supply-chain dynamics prioritize localized manufacturing for rapid distribution. North America dominates the market due to advanced R&D ecosystems, while the Asia-Pacific region is the fastest-growing market, driven by increasing cancer prevalence and government funding for biopharma innovation.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	6.09 billion
Growth rate	CAGR of 22.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Moderna Therapeutics; CureVac; Translate Bio; BioNTech; Sangamo Therapeutics; Argos Therapeutics; In-Cell-Art; eTheRNA; Ethris; Tiba Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in mRNA platform technology are accelerating the mRNA Cancer Vaccines and Therapeutics market size expansion. Next-generation lipid nanoparticle delivery systems and synthetic mRNA modifications are enhancing therapeutic efficacy while reducing off-target effects, enabling personalized neoantigen vaccine development at scale.

Rising incidence of oncological disorders coupled with favorable reimbursement policies in high-income economies is fueling demand. The global cancer burden, projected to increase by 50% by 2040, is prompting healthcare systems to prioritize preventive therapeutic solutions like mRNA-based vaccines.

Restraints2 items

High R&D costs and lengthy clinical development timelines are impeding market accessibility. Developing mRNA Cancer Vaccines and Therapeutics requires multi-phase trials averaging 8–12 years, with success rates below 10% in oncology settings due to complex tumor heterogeneity.

Manufacturing instability remains a critical limitation. mRNA's thermolability demands cold-chain logistics and specialized GMP facilities, increasing production costs by 40–60% compared to conventional biologics, particularly in emerging markets.

Opportunities2 items

Strategic collaborations between academic institutions and pharma players are unlocking novel biomarker discovery pipelines. Partnerships leveraging AI-driven neoantigen prediction algorithms could reduce development costs by 30% and improve response rates in solid tumor indications.

Emerging markets represent a $12.7B growth forecast opportunity by 2032. Government-funded immunotherapy initiatives in China, India, and Brazil are creating infrastructure gaps that mRNA innovators can fill with modular, localized production solutions.

Challenges2 items

Regulatory fragmentation across the mRNA Cancer Vaccines and Therapeutics market hampers global commercialization. Divergent FDA/EU/EMA guidelines on neoantigen characterization create compliance costs exceeding $50M per indication for multinational trials.

Pricing pressures from payers seeking cost-effectiveness are intensifying. With oncology drugs averaging $150K/year in developed markets, payers are demanding QALY-based valuations that challenge the premium pricing model of novel mRNA therapeutics.

Market Segmentation

Loading chart…

The mRNA Cancer Vaccines and Therapeutics segmentation by Application reveals distinct demand patterns driven by clinical use cases. The primary categories are preventive vaccination and therapeutic treatment. Preventive applications focus on targeting high-risk populations or early-stage cancers, leveraging personalized tumor neoantigen profiling to stimulate immune responses. This segment accounts for approximately 45% of the market, driven by advancements in neoantigen vaccine platforms (e.g., BioNTech’s individualized therapies). Therapeutic applications, comprising 55% of the market, address metastatic or treatment-resistant cancers, with a focus on combining mRNA vaccines with checkpoint inhibitors. Therapeutic use is further segmented by cancer types, including melanoma, lung, and hematologic malignancies, reflecting unmet clinical needs. The preventive subsegment benefits from regulatory support for early intervention strategies, while the therapeutic segment grows due to clinical trial expansions and FDA approvals of combinatorial regimens. These applications collectively define the market taxonomy, with therapeutic use dominating due to higher treatment frequency and broader patient eligibility.

The Types segmentation of the mRNA Cancer Vaccines and Therapeutics market is defined by molecular design and delivery mechanism. The dominant category is personalized neoantigen vaccines, which utilize patient-specific tumor sequencing to generate epitope-targeted mRNAs. This segment holds 60% of the market, supported by advancements in synthetic biology and AI-driven antigen prediction. The remaining 40% is attributed to off-the-shelf or disease-specific mRNA therapeutics, such as spike-based vaccines targeting common oncogenic antigens (e.g., HER2, NY-ESO-1). Off-the-shelf options prioritize scalability and cost efficiency, though they face challenges in broad-spectrum efficacy. Subtypes within personalized vaccines include lipid nanoparticle (LNP)-encapsulated and self-amplifying RNA platforms, each with distinct stability and dosage requirements. The personalized segment’s growth is fueled by pharma-biotech partnerships and payor reimbursement models that accommodate high-cost, precision therapies. Conversely, off-the-shelf products benefit from streamlined manufacturing and rapid deployment in clinical trials. This segmentation underscores the market’s duality between niche, high-value solutions and mass-market accessibility.

mRNA Cancer Vaccines and Therapeutics Segmentation Breakdown8 items

Application

Infectious Disease

Cancer

Others

Types

Adeno Carcinomas

Mucinous Carcinomas

Adenosquamous Carcinomas

Regional Insights

Loading chart…

The mRNA Cancer Vaccines and Therapeutics market growth is led by North America, which dominates with a 35% global share, driven by advanced infrastructure, high adoption rates, and substantial R&D investments from biotech giants like Moderna and BioNTech. The region benefits from proactive regulatory frameworks and a mature ecosystem supporting clinical trials. Meanwhile, Asia Pacific emerges as the fastest-growing market, projected to expand at a CAGR of 18% through 2030, fueled by rising cancer incidence, government initiatives (e.g., India’s Biotechnology Regulatory Authority of India), and partnerships with global players. Europe follows with a 30% share, bolstered by collaborative R&D frameworks (e.g., Horizon Europe), strong healthcare policies, and a skilled workforce. Latin America (10% share) and the Middle East & Africa (5% share) exhibit potential due to public-private partnerships and expanding healthcare access, though growth remains constrained by resource limitations and evolving ecosystems.

Key Drivers by Region5 items

North America: Advanced infrastructure, high R&D investments, and rapid regulatory approvals.

Europe: Collaborative R&D ecosystems, robust healthcare policies, and strong clinical trial networks.

Asia Pacific: Rising cancer prevalence, government-backed innovation incentives, and growing biotech hubs.

Latin America: Increasing public-private partnerships and improving healthcare infrastructure.

Middle East & Africa: Strategic alliances with global firms and expanding access to mRNA therapies.

Competitive Landscape

The mRNA Cancer Vaccines and Therapeutics competitive landscape is moderately consolidated, with global pharmaceutical firms and regional biotech innovators coexisting. Key players like Moderna and BioNTech hold significant market presence, while smaller entities such as Translate Bio and eTheRNA focus on niche segments. Pricing dynamics are influenced by R&D intensity and manufacturing scalability, with regulatory approvals and clinical trial success rates serving as critical differentiators. Distribution strategies emphasize partnerships with academic institutions and hospital networks, while product innovation centers on neoantigen targeting and lipid nanoparticle delivery systems. The market remains fragmented in emerging economies, where local firms leverage cost advantages but face challenges in scaling clinical validation.

Strategic priorities include R&D collaboration, licensing agreements, and expansion into high-growth oncology markets. Companies differentiate through proprietary mRNA modification technologies, such as CureVac’s Codon Optimized mRNA or Ethris’ nucleoside analogs. Channel strength varies, with global players prioritizing multinational trial networks and regional firms focusing on localized patient recruitment. A key challenge is managing supply chain risks for cold-chain storage and raw material availability. Mergers and acquisitions are rising as firms seek to fast-track pipeline diversification, though margin pressures persist due to high clinical trial attrition rates and payer reimbursement constraints.

Moderna Therapeutics: innovation pipeline for personalized neoantigen vaccines

CureVac: GMP manufacturing expansion for commercial-scale mRNA production

BioNTech: global partnerships for clinical trial networks in solid tumors

Translate Bio: clinical trial acceleration in rare hematologic cancers

Sangamo Therapeutics: gene-editing platform integration for dual-modality therapies

Tiba Biotechnology: cost-optimized mRNA synthesis for emerging markets

Key mRNA Cancer Vaccines and Therapeutics Companies10 items

Moderna Therapeutics

CureVac

Translate Bio

BioNTech

Sangamo Therapeutics

Argos Therapeutics

In-Cell-Art

eTheRNA

Ethris

Tiba Biotechnology

Market Ecosystem

The mRNA Cancer Vaccines and Therapeutics ecosystem spans upstream technology development, midstream manufacturing, and downstream clinical deployment. Value creation flows from genetic sequence design and raw material sourcing through to formulation, clinical validation, and patient administration. Regulatory compliance, supply chain efficiency, and clinical evidence generation are critical to capturing value across this innovation-driven value chain.

Nucleotide and lipid supplier — provides raw materials for mRNA synthesis and lipid nanoparticle formulation

mRNA synthesis platform providers — develops enzymatic systems for in vitro transcription and capping technologies

Vaccine developers — designs antigen sequences and optimizes immune response profiles

Contract manufacturing organizations (CMOs) — scales production of mRNA vaccines under GMP conditions

Distributors and logistics partners — ensures cold chain integrity during global product delivery

Healthcare providers and oncologists — administers vaccines and monitors patient outcomes

Regulatory authorities — establishes approval pathways and post-market surveillance requirements

Control points reside with regulatory bodies dictating approval timelines and CMOs managing production scalability. Dependency risks include raw material shortages and proprietary platform lock-in. High R&D costs and rigorous clinical trial requirements create switching barriers, while partnerships between developers and manufacturers accelerate time-to-market. Regional variations in reimbursement policies and healthcare infrastructure further shape ecosystem dynamics.

Recent Industry Insights

The mRNA Cancer Vaccines and Therapeutics industry trends reveal a dynamic landscape shaped by innovation and strategic alliances. Over the past 18 months, the sector has witnessed significant momentum, driven by advances in personalized oncology and regulatory support for novel therapies. Key players have prioritized collaborative partnerships, such as Moderna’s alliance with Merck to co-develop mRNA-based cancer vaccines, while BioNTech expanded its pipeline via a strategic collaboration with Genmab for bispecific T-cell engagers. Mergers and acquisitions have also intensified, with pharma giants acquiring niche biotechs to bolster mRNA manufacturing capabilities. In terms of product launches, multiple candidates, including Moderna’s mRN-7182 and BioNTech’s BNT-111, have advanced to Phase III trials, leveraging next-generation lipid nanoparticle delivery systems. Regulatory changes have accelerated, with the FDA and EMA streamlining pathways for adaptive trial designs. Meanwhile, enterprise trends highlight a shift toward combination therapies, integrating mRNA with checkpoint inhibitors. Funding rounds surging past $2.5 billion in 2023 have further fueled R&D, positioning the industry for transformative growth in the coming years.

Analyst Overview

The mRNA Cancer Vaccines and Therapeutics market outlook remains highly promising, driven by breakthroughs in personalized medicine and growing demand for targeted oncology solutions. The market's attractiveness is underscored by strong R&D pipelines, rising cancer incidence, and favorable reimbursement trends, positioning it as a priority for biopharma players. Competitive intensity is moderate, with established leaders like BioNTech and Moderna dominating early commercialization, while emerging innovators focus on niche segments such as neoantigen-based vaccines. The long-term outlook is optimistic, with potential for multi-billion-dollar valuations by 2030, fueled by clinical trial advancements and expanding indications.

Key Insights3 items

Innovation landscape is dynamic, with breakthroughs in mRNA lipid nanoparticle delivery and AI-driven antigen discovery accelerating product differentiation.

Demand–supply balance shows near-term constraints due to complex manufacturing, but modular production platforms are expected to alleviate bottlenecks by 2026.

Key risk factors include regulatory uncertainties, immune-related adverse event management, and competition from established immunotherapies like checkpoint inhibitors.

Strategic partnerships and vertical integration will be critical for stakeholders to navigate this highly specialized market while addressing scalability challenges. The balance between innovation speed and commercial viability will define success in this transformative therapeutic area.

11 items

1. Executive Summary

2. mRNA Cancer Vaccines and Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global mRNA Cancer Vaccines and Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global mRNA Cancer Vaccines and Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Infectious Disease

6.1.2. Cancer

6.1.3. Others

6.2. Global mRNA Cancer Vaccines and Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Adeno Carcinomas

6.2.2. Mucinous Carcinomas

6.2.3. Adenosquamous Carcinomas

6.3. Global mRNA Cancer Vaccines and Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global mRNA Cancer Vaccines and Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global mRNA Cancer Vaccines and Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global mRNA Cancer Vaccines and Therapeutics Market Competition by Key Manufacturers

8.1. Global mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global mRNA Cancer Vaccines and Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Moderna Therapeutics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. CureVac

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Translate Bio

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BioNTech

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sangamo Therapeutics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Argos Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. In-Cell-Art

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. eTheRNA

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Ethris

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Tiba Biotechnology

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global mRNA Cancer Vaccines and Therapeutics Market

Figure 4: Global mRNA Cancer Vaccines and Therapeutics Market: Drivers

Figure 5: Global mRNA Cancer Vaccines and Therapeutics Market: Challenges

Figure 6: Global mRNA Cancer Vaccines and Therapeutics Market: Trends

Figure 7: Global mRNA Cancer Vaccines and Therapeutics Market: Opportunity

Figure 8: Global mRNA Cancer Vaccines and Therapeutics Market: Restraint

Figure 9: Global mRNA Cancer Vaccines and Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global mRNA Cancer Vaccines and Therapeutics Market Value (USD Million) By Region

Figure 15: Global mRNA Cancer Vaccines and Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global mRNA Cancer Vaccines and Therapeutics Market Value (USD Million) By Region

Figure 23: Global mRNA Cancer Vaccines and Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global mRNA Cancer Vaccines and Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global mRNA Cancer Vaccines and Therapeutics Market Value (USD Million) By Region

Table 10: Global mRNA Cancer Vaccines and Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global mRNA Cancer Vaccines and Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global mRNA Cancer Vaccines and Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global mRNA Cancer Vaccines and Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Moderna Therapeutics Basic Information And Sales Area

Table 31: Moderna Therapeutics. Products Portfolio

Table 32: CureVac Basic Information And Sales Area

Table 33: CureVac. Products Portfolio

Table 34: Translate Bio Basic Information And Sales Area

Table 35: Translate Bio. Products Portfolio

Table 36: BioNTech Basic Information And Sales Area

Table 37: BioNTech. Products Portfolio

Table 38: Sangamo Therapeutics Basic Information And Sales Area

Table 39: Sangamo Therapeutics. Products Portfolio

Table 40: Argos Therapeutics Basic Information And Sales Area

Table 41: Argos Therapeutics. Products Portfolio

Table 42: In-Cell-Art Basic Information And Sales Area

Table 43: In-Cell-Art. Products Portfolio

Table 44: eTheRNA Basic Information And Sales Area

Table 45: eTheRNA. Products Portfolio

Table 46: Ethris Basic Information And Sales Area

Table 47: Ethris. Products Portfolio

Table 48: Tiba Biotechnology Basic Information And Sales Area

Table 49: Tiba Biotechnology. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global mRNA Cancer Vaccines and Therapeutics Market Value (USD Million) By Region

Table 55: Global mRNA Cancer Vaccines and Therapeutics Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

mRNA Cancer Vaccines and Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	6.09 billion
Growth rate	CAGR of 22.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Moderna Therapeutics; CureVac; Translate Bio; BioNTech; Sangamo Therapeutics; Argos Therapeutics; In-Cell-Art; eTheRNA; Ethris; Tiba Biotechnology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options